A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.


Updates from The Motley Fool

Latest updates on Alkermes from Fool.com.  The Fool has written over 100 articles on Alkermes.
Alkermes' Revenue Jumps 22%

Strong sales growth in the company's proprietary products helped power Alkermes' top line higher.

5 Biotech Predictions for 2016

A win and loss for marijuana, a big advance in Alzheimer's disease, and the next big thing are am...

This Week in Biotech

A late-stage trial stopped early due to highly statistically significant efficacy, a major biopha...



Stock Performance

View Interactive ALKS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alkermes.
Current Price: $57.53
Prev Close: $57.53
Open: $57.90
Bid: $41.09
Ask: $58.00
Day's Range: $57.27 - $57.95
52wk Range: $41.93 - $63.40
Volume: 660,803
Avg Vol 848,630
Market Cap: $9B
P/E (ttm): -43.65
EPS (ttm): ($1.32)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alkermes.
CAPS Rating 5 out of 5
 
336 Outperform
12 Underperform
CAPS All Stars
 
98 Outperform
2 Underperform

How do you think Alkermes will perform against the market?



You pick for Alkermes is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Richard F. Pops, CEO

100% Approve

Based on 37 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alkermes.

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers